Whilst headline H1 revenue growth of 23% is eye-catching, for us the most comforting factor is the robust performance of the underlying business in the most challenging of circumstances. Sales of the Primestore MTM sample collection device contributed £6.5m, meaning the core business was -8% in the period, well ahead of internal expectations. Highlights include strong performances from BhB, DiaSpect Tm and the Clinical Chemistry portfolio, all of which grew revenues in the period. Whils
14 Sep 2020
Interims highlight robust underlying performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims highlight robust underlying performance
EKF Diagnostics Holdings plc (EKF:LON) | 27.8 0 0.0% | Mkt Cap: 126.1m
- Published:
14 Sep 2020 -
Author:
Chris Glasper -
Pages:
3
Whilst headline H1 revenue growth of 23% is eye-catching, for us the most comforting factor is the robust performance of the underlying business in the most challenging of circumstances. Sales of the Primestore MTM sample collection device contributed £6.5m, meaning the core business was -8% in the period, well ahead of internal expectations. Highlights include strong performances from BhB, DiaSpect Tm and the Clinical Chemistry portfolio, all of which grew revenues in the period. Whils